{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:37:37Z","timestamp":1771486657897,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.clgc.2022.12.010","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T02:32:54Z","timestamp":1672799574000},"page":"e190-e197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of Bisphosphonates on Skeletal Related Events in Long Bone Metastases of Renal Cell Carcinoma: A Systematic Review"],"prefix":"10.1016","volume":"21","author":[{"given":"Danique LM","family":"van Broekhoven","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa W","family":"Dootjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carola","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"van Oldenrijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.12.010_bib0001","first-page":"79","article-title":"Epidemiology of renal cell carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J Oncol"},{"key":"10.1016\/j.clgc.2022.12.010_bib0002","first-page":"1135","article-title":"Treating patients with renal cell carcinoma and bone metastases","volume":"18","author":"Guida","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clgc.2022.12.010_bib0003","first-page":"284","article-title":"Skeletal metastasis in renal cell carcinoma: current and future management options","volume":"38","author":"Wood","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2022.12.010_bib0004","first-page":"160","article-title":"Skeletal complications and survival in renal cancer patients with bone metastases","volume":"48","author":"Woodward","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.clgc.2022.12.010_bib0005","first-page":"405","article-title":"Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis","volume":"28","author":"Yuasa","year":"2011","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.clgc.2022.12.010_bib0006","first-page":"163","article-title":"Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone","volume":"52","author":"Toyoda","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.12.010_bib0007","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.clgc.2022.12.010_bib0008","first-page":"e83026","article-title":"Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey","volume":"8","author":"Santini","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2022.12.010_bib0009","article-title":"Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid","volume":"10","author":"Lipton","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2022.12.010_bib0010","first-page":"511","article-title":"An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma","volume":"15","author":"Gr\u00fcnwald","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2022.12.010_bib0011","first-page":"89","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.clgc.2022.12.010_bib0012","first-page":"712","article-title":"Methodological index for non-randomized studies (MINORS): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.clgc.2022.12.010_bib0013","first-page":"962","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2022.12.010_bib0014","first-page":"964","article-title":"Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers","volume":"96","author":"Saad","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2022.12.010_bib0015","first-page":"497","article-title":"Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma","volume":"107","author":"Tannir","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2022.12.010_bib0016","first-page":"620","article-title":"Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate","volume":"103","author":"Kijima","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2022.12.010_bib0017","first-page":"81","article-title":"Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma","volume":"9","author":"Manoukian","year":"2011","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2022.12.010_bib0018","first-page":"770","article-title":"Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up","volume":"17","author":"Takeda","year":"2012","journal-title":"J Orthop Sci"},{"key":"10.1016\/j.clgc.2022.12.010_bib0019","first-page":"6261","article-title":"Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases","volume":"19","author":"Tunn","year":"2012","journal-title":"Can J Urol"},{"key":"10.1016\/j.clgc.2022.12.010_bib0020","first-page":"877","article-title":"Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma","volume":"18","author":"Yasuda","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.12.010_bib0021","first-page":"1532","article-title":"Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma","volume":"71","author":"Smidt-Hansen","year":"2013","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.clgc.2022.12.010_bib0022","first-page":"502","article-title":"Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma","volume":"66","author":"McKay","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.12.010_bib0023","first-page":"1127","article-title":"Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis","volume":"23","author":"Hosaka","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.12.010_bib0024","first-page":"100","article-title":"A phase II study of palliative radiotherapy combined with zoledronic acid hydrate for metastatic bone tumour from renal cell carcinoma","volume":"51","author":"Harada","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.12.010_bib0025","first-page":"3150","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.12.010_bib0026","first-page":"8219","article-title":"Bisphosphonates for treatment and prevention of bone metastases","volume":"23","author":"Michaelson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.12.010_bib0027","first-page":"1479","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clgc.2022.12.010_bib0028","first-page":"743","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.12.010_bib0029","first-page":"3082","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomized, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322002683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322002683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:36:49Z","timestamp":1761565009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322002683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1558767322002683"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.12.010","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Bisphosphonates on Skeletal Related Events in Long Bone Metastases of Renal Cell Carcinoma: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}